The tweet was deleted by the author.
But we saved everything 🙂.
Invivyd has announced positive topline results from its LIBERTY Phase 3 study of VYD2311, indicating superior safety and tolerability compared to mRNA-based COVID-19 vaccines.
The company also outlined plans to submit regulatory filings for VYD2311. Further details on approval timelines or commercial plans were not disclosed.
View post on X Loading...